garem1 Antibody

What is GAREM1 and why is it significant for cell signaling research?

GAREM1 (GRB2 associated regulator of MAPK1 subtype 1) is an adaptor protein that plays a crucial role in intracellular signaling cascades. It functions primarily in pathways triggered by the epidermal growth factor receptor (EGFR) and cytoplasmic protein tyrosine kinases . As a member of the GAREM protein family, it mediates interactions between proteins and regulates various cellular processes including proliferation, migration, and differentiation .

The significance of GAREM1 extends to multiple research areas:

• Signal transduction pathway investigation

• Cancer research and oncogenic signaling

• Cell proliferation and migration studies

• Protein-protein interaction networks

The protein consists of 876 amino acid residues in its canonical form and can exist in three different isoforms resulting from alternative splicing . Its involvement in diseases such as cancer, diabetes, and neurodegenerative disorders makes it a valuable target for both basic research and therapeutic development .

What are the primary applications for GAREM1 antibodies in research?

GAREM1 antibodies have been validated for multiple research applications, each providing unique insights into protein expression, localization, and function:

These applications allow researchers to:

• Detect native GAREM1 protein in cell lysates and tissue samples

• Visualize expression patterns across different cell types

• Study changes in GAREM1 expression under various experimental conditions

• Investigate protein-protein interactions through co-immunoprecipitation

When selecting the appropriate application, researchers should consider their specific research question, sample type, and required sensitivity level.

How should researchers select the most appropriate GAREM1 antibody for their experiments?

Selecting the optimal GAREM1 antibody requires consideration of multiple technical factors to ensure experimental success:

Antibody Type Considerations:

• Polyclonal antibodies (such as rabbit-derived PACO40586) offer high sensitivity by recognizing multiple epitopes, making them ideal for detecting low-abundance proteins

• Monoclonal antibodies provide higher specificity and reproducibility for repeated experiments

• Host species selection (commonly rabbit for GAREM1) should avoid cross-reactivity with secondary detection systems

Technical Selection Criteria:

• Epitope location: Consider antibodies targeting different regions based on your research needs (C-terminal, N-terminal, or specific domains)

• Validation data: Review immunohistochemistry images and Western blot results provided by manufacturers

• Reactivity spectrum: Ensure compatibility with your experimental species (human samples for most commercially available GAREM1 antibodies)

• Application validation: Verify the antibody has been tested for your specific application (WB, IHC, IF, etc.)

For research focusing on specific GAREM1 regions, note that some antibodies target the C-terminal region while others (like the antibody described in the scientific literature) target specific fragments (residues 391-488) .

What are the recommended protocols for Western blot detection of GAREM1?

Optimized Western blot protocols for GAREM1 detection require careful attention to sample preparation, electrophoresis conditions, and detection parameters:

Sample Preparation:

• Lyse cells in RIPA buffer supplemented with protease and phosphatase inhibitors

• Centrifuge at 14,000g for 15 minutes at 4°C to remove debris

• Quantify protein concentration using BCA or Bradford assay

• Prepare 20-50 μg of total protein per lane with reducing sample buffer

Electrophoresis and Transfer:

• Resolve proteins on 8-10% SDS-PAGE (appropriate for the 97.2 kDa GAREM1 protein)

• Transfer to PVDF membrane at 100V for 90 minutes in cold transfer buffer

• Verify transfer efficiency with reversible protein stain

Immunodetection:

• Block membrane with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Incubate with primary GAREM1 antibody (1:2000-1:5000 dilution) overnight at 4°C

• Wash 3-5 times with TBST (5 minutes each)

• Incubate with HRP-conjugated secondary antibody (1:5000-1:10000) for 1 hour at room temperature

• Wash 3-5 times with TBST

• Develop using enhanced chemiluminescence and appropriate imaging system

Critical Controls:

• Positive control: Cell lysate known to express GAREM1 (e.g., prostate cancer cell lines)

• Negative control: GAREM1-knockout or siRNA-treated cell lysate

• Loading control: β-actin or GAPDH antibody detection

For phosphorylated GAREM1 detection, specialized phospho-specific antibodies and phosphatase inhibitors are essential throughout the protocol .

How can researchers optimize immunohistochemistry protocols for GAREM1 detection in tissue samples?

Successful immunohistochemical detection of GAREM1 in tissue sections requires optimization of several critical parameters:

Tissue Preparation:

• Fix tissue samples in 10% neutral buffered formalin for 24-48 hours

• Process and embed in paraffin using standard histological procedures

• Section at 4-6 μm thickness onto adhesive slides

• Deparaffinize and rehydrate through graded alcohols to water

Antigen Retrieval Methods (comparative effectiveness):

Staining Protocol:

• Block endogenous peroxidase activity (3% H₂O₂, 10 minutes)

• Block non-specific binding (5-10% normal serum from secondary antibody species)

• Apply primary GAREM1 antibody at optimized dilution (1:20-1:200)

• Incubate in humidified chamber (overnight at 4°C or 1-2 hours at room temperature)

• Apply appropriate detection system (e.g., polymer-based HRP detection)

• Develop with DAB substrate and counterstain with hematoxylin

• Dehydrate, clear, and mount

Optimization Strategies:

• Perform antibody dilution series (1:20, 1:50, 1:100, 1:200) to determine optimal concentration

• Compare different antigen retrieval methods for your specific tissue type

• Validate specificity using prostate cancer tissue sections as positive controls

• Include isotype control antibodies at matching concentrations

These protocols have been validated for human prostate cancer tissue, where GAREM1 shows specific expression patterns that can be clearly visualized using proper immunohistochemical techniques .

What are the recommended approaches for immunofluorescence studies of GAREM1?

Immunofluorescence provides valuable insights into GAREM1 subcellular localization and potential co-localization with interacting proteins. The following methodology optimizes detection while minimizing background:

Cell Preparation:

• Culture cells on glass coverslips or chamber slides to 70-80% confluence

• Fix cells using one of these methods:

  • 4% paraformaldehyde (10 minutes at room temperature) for preserving structure

  • Ice-cold methanol (5 minutes at -20°C) for enhanced epitope accessibility

Immunostaining Protocol:

• Permeabilize cells with 0.1-0.5% Triton X-100 in PBS (5 minutes at room temperature)

• Block with 1-5% BSA or 5-10% normal serum in PBS (30-60 minutes)

• Incubate with primary GAREM1 antibody diluted 1:50-1:200 in blocking buffer (overnight at 4°C or 1-2 hours at room temperature)

• Wash 3x with PBS (5 minutes each)

• Incubate with fluorophore-conjugated secondary antibody (1:500-1:1000) for 1 hour at room temperature (protected from light)

• Wash 3x with PBS

• Counterstain nuclei with DAPI (1 μg/ml, 5 minutes)

• Mount with anti-fade mounting medium

Advanced Co-localization Studies:
For investigating GAREM1 interactions with signaling partners:

• Use compatible primary antibodies from different host species (e.g., rabbit anti-GAREM1 with mouse anti-EGFR)

• Apply both primary antibodies simultaneously during the incubation step

• Use spectrally distinct secondary antibodies (e.g., Alexa Fluor 488 and 594)

• Analyze co-localization using confocal microscopy and appropriate software

Critical Controls:

• Omission of primary antibody to assess secondary antibody specificity

• Peptide competition assay using the immunizing peptide sequence to verify specific binding

• GAREM1-knockout or knockdown cells as negative controls

This approach allows precise visualization of GAREM1 distribution patterns and potential associations with other signaling molecules, particularly in the context of EGF receptor pathways .

How can researchers investigate GAREM1 phosphorylation dynamics in response to growth factor stimulation?

GAREM1 undergoes phosphorylation as a key regulatory mechanism in growth factor signaling pathways. Investigating these dynamics requires specialized techniques:

Experimental Design for Phosphorylation Studies:

• Serum-starve cells for 12-24 hours to reduce basal phosphorylation

• Stimulate with EGF (10-100 ng/ml) for various time points (0, 5, 15, 30, 60 minutes)

• Rapidly lyse cells in buffer containing phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate)

• Perform either:

  • Immunoprecipitation with GAREM1 antibody followed by phosphotyrosine detection (4G10 antibody)

  • Direct Western blot with phospho-specific GAREM1 antibodies if available

Analysis of Phosphorylation-Dependent Interactions:
GAREM1 serves as an adapter protein that, upon phosphorylation, creates binding sites for SH2 domain-containing proteins such as Grb2 . To study these interactions:

• Perform co-immunoprecipitation experiments using:

  • Anti-GAREM1 antibody for pulldown followed by Grb2, SHP2, or SOS1 detection

  • GST-fusion proteins containing specific SH2 domains to capture phosphorylated GAREM1

• Compare interaction profiles between:

  • Unstimulated cells

  • Growth factor-stimulated cells

  • Cells treated with tyrosine kinase inhibitors

Quantification Approach:

• Normalize phospho-GAREM1 signal to total GAREM1 protein

• Plot time-course data to identify peak phosphorylation events

• Compare phosphorylation kinetics with downstream MAPK activation (using phospho-ERK1/2 antibodies)

This methodological approach allows researchers to position GAREM1 within the temporal sequence of signaling events following growth factor receptor activation and understand its role in signal transduction .

What methods can be used to distinguish between different GAREM1 isoforms?

Distinguishing between the three reported GAREM1 isoforms requires strategic experimental approaches that exploit their structural differences:

Western Blot Discrimination Strategy:

• Select antibodies targeting different epitopes:

  • Common regions (for detecting all isoforms simultaneously)

  • Isoform-specific regions (for selective detection)

• Use high-resolution SDS-PAGE (7.5-8% gels with extended run times) to separate closely migrating isoforms

• Create reference standards by expressing recombinant tagged versions of each isoform

Expected Molecular Weight Pattern:

RT-PCR and qPCR Approaches:

• Design primer pairs spanning:

  • Exon junctions unique to specific isoforms

  • Alternatively spliced regions

• Perform RT-PCR to visualize distinct amplicon sizes

• Use isoform-specific qPCR for quantitative expression analysis across tissues or experimental conditions

Immunoprecipitation-Mass Spectrometry:
For definitive isoform identification:

• Immunoprecipitate GAREM1 using an antibody recognizing all isoforms

• Perform tryptic digestion of purified protein

• Analyze peptide fragments by LC-MS/MS

• Identify unique peptide sequences corresponding to specific isoforms

Understanding isoform-specific expression patterns may provide insights into specialized functions of GAREM1 variants in different cellular contexts or disease states .

What approaches can researchers use to study GAREM1's role in the EGFR-MAPK signaling pathway?

Investigating GAREM1's functional role in EGFR-MAPK signaling requires complementary approaches that address both molecular interactions and cellular outcomes:

Molecular Interaction Studies:

• Sequential Co-immunoprecipitation:

  • Immunoprecipitate with anti-EGFR antibody after EGF stimulation

  • Probe for GAREM1 recruitment

  • Subsequently analyze associated proteins (Grb2, SHP2, SOS1)

• Domain Mapping Experiments:

  • Express truncated GAREM1 constructs lacking specific domains

  • Assess their ability to interact with pathway components

  • Identify critical regions for protein-protein interactions

Functional Signaling Assays:

• MAPK Pathway Activation Analysis:

  • Manipulate GAREM1 expression (overexpression, knockdown, or knockout)

  • Stimulate cells with EGF at various concentrations and timepoints

  • Monitor downstream signaling by measuring:

    • ERK1/2 phosphorylation dynamics

    • AKT activation

    • Transcriptional responses

• Quantitative Pathway Analysis:

  • Create dose-response and time-course profiles of MAPK activation

  • Compare between GAREM1-manipulated and control conditions

  • Analyze signal duration, amplitude, and activation threshold changes

Cellular Outcome Assessment:

• Proliferation Assays:

  • MTT or BrdU incorporation in cells with altered GAREM1 expression

  • Colony formation assays to assess long-term growth effects

• Migration Studies:

  • Wound healing assays

  • Transwell migration experiments

  • Time-lapse microscopy to track cell movement

• Differentiation Analysis:

  • Lineage-specific marker expression

  • Morphological changes associated with differentiation

These complementary approaches provide a comprehensive understanding of how GAREM1 contributes to signal transduction from activated growth factor receptors to downstream MAPK pathway components, ultimately affecting biological outcomes .

What are common issues with GAREM1 antibody specificity and how can researchers address them?

Ensuring antibody specificity is critical for generating reliable GAREM1 research data. Several challenges and their solutions include:

Common Specificity Issues:

Validation Strategies:

• Genetic Validation:

  • Compare wild-type vs. GAREM1 knockout/knockdown samples

  • Expect complete absence or significant reduction of specific signal

• Peptide Competition:

  • Pre-incubate antibody with excess immunizing peptide

  • Specific signals should be blocked while non-specific signals persist

  • Particularly useful for antibodies raised against specific peptide sequences

• Orthogonal Technique Comparison:

  • Compare protein detection across multiple techniques (WB, IHC, IF)

  • Consistent patterns across methods suggest specificity

  • Inconsistent results warrant further investigation

• Multiple Antibody Approach:

  • Use antibodies targeting different GAREM1 epitopes

  • Concordant results increase confidence in specificity

GAREM1 shares sequence similarity with GAREM2 (FAM59B), requiring careful validation to avoid cross-reactivity. When selecting antibodies, prioritize those with documented specificity testing against related family members .

What factors influence successful detection of GAREM1 in different experimental systems?

Detection success varies across experimental systems and can be optimized through consideration of multiple factors:

Cell/Tissue-Specific Considerations:

Technical Optimization Factors:

• Sample Preparation:

  • For Western blot: Include phosphatase/protease inhibitors to prevent degradation

  • For IHC/IF: Optimize fixation time to preserve epitope accessibility

  • For all applications: Proper sample storage to prevent protein degradation

• Antibody Selection:

  • Primary antibody concentration: Titrate to determine optimal signal-to-noise ratio

  • Secondary antibody matching: Ensure proper species compatibility and minimal cross-reactivity

  • Detection system: Consider HRP-polymer systems for IHC or high-sensitivity fluorophores for IF

• Signal Enhancement Strategies:

  • For low-abundance detection: TSA (tyramide signal amplification) in IHC/IF

  • For Western blot: Extended exposure times with low-background substrates

  • For all methods: Reduce background through additional blocking/washing steps

By systematically optimizing these parameters, researchers can improve detection sensitivity while maintaining specificity, enabling successful GAREM1 detection across diverse experimental systems .

How should researchers validate the functionality of new GAREM1 antibody lots?

Antibody lot-to-lot variation can significantly impact experimental results. A systematic validation approach ensures consistent performance:

Comprehensive Validation Protocol:

• Physical Characterization:

  • Verify antibody concentration using A280 measurement

  • Check for visible precipitation or contamination

  • Confirm proper storage conditions have been maintained

• Performance Comparison:

  • Run side-by-side Western blots with previous validated lot

  • Compare band patterns, intensity, and background

  • Document settings (exposure time, sample amount) for future reference

• Dilution Series Optimization:

  • Test multiple dilutions around the manufacturer's recommended range

  • Create standard curves of signal vs. antibody concentration

  • Determine the optimal working concentration for the new lot

• Cross-Application Validation:

  • If using for multiple applications (WB, IHC, IF), validate each separately

  • Document application-specific optimal conditions

  • Note any application-specific limitations

Documentation Requirements:

• Create a validation report with images from each test

• Record lot number, receipt date, and expiration date

• Document all optimization parameters

• Maintain this information in laboratory records for reproducibility

When significant variations are observed between lots, researchers should contact the manufacturer for technical support and consider requesting replacement or alternative GAREM1 antibodies to maintain experimental consistency and reliability .

How can researchers quantitatively analyze GAREM1 expression patterns across different experimental conditions?

Quantitative analysis of GAREM1 expression requires rigorous methodological approaches tailored to specific experimental techniques:

Western Blot Quantification:

• Densitometry Protocol:

  • Capture non-saturated images (verify with dynamic range testing)

  • Measure integrated density of GAREM1 bands using ImageJ or similar software

  • Subtract local background for each lane

  • Normalize to loading controls (β-actin, GAPDH)

  • Present as fold-change relative to control conditions

• Statistical Analysis:

  • Perform at least three independent biological replicates

  • Apply appropriate statistical tests (t-test for paired comparisons, ANOVA for multiple groups)

  • Report means with standard deviation or standard error

Immunohistochemistry Quantification:

• Semi-quantitative Scoring:

  • Develop a scoring system (0-3+) based on staining intensity

  • Score multiple fields per sample by at least two independent observers

  • Calculate H-score (sum of percentage of cells at each intensity level × intensity)

• Digital Pathology Analysis:

  • Scan stained sections with digital slide scanner

  • Use image analysis software to:

    • Segment positive and negative cells

    • Measure staining intensity (optical density)

    • Determine percentage of positive cells

  • Validate algorithm against pathologist scoring

Immunofluorescence Quantification:

• Single-cell Analysis:

  • Acquire Z-stack images by confocal microscopy

  • Segment individual cells using nuclear counterstain

  • Measure mean fluorescence intensity within defined cellular compartments

  • Compare distributions between experimental groups

This systematic approach to quantification enables objective comparison of GAREM1 expression across experimental conditions, providing robust data for statistical analysis and interpretation .

What considerations are important when analyzing GAREM1's role in complex signaling networks?

GAREM1 functions within intricate signaling networks, requiring sophisticated analytical approaches:

Network Analysis Considerations:

• Temporal Dynamics:

  • Design time-course experiments (5-60 minutes post-stimulation)

  • Consider both early (phosphorylation) and late (transcriptional) events

  • Analyze activation/deactivation kinetics and feedback loops

• Pathway Crosstalk:

  • Simultaneously monitor multiple pathways (MAPK, PI3K/Akt, JAK/STAT)

  • Use pathway-specific inhibitors to dissect contributions

  • Create network models incorporating observed interactions

• Context Dependency:

  • Compare GAREM1 function across cell types with different receptor expression levels

  • Examine effects of cell density, matrix composition, and other microenvironmental factors

  • Test pathway activation under physiological vs. pathological conditions

Advanced Analytical Approaches:

• Phosphoproteomics:

  • Perform global phosphoproteomic analysis in GAREM1-manipulated cells

  • Identify differentially phosphorylated proteins after growth factor stimulation

  • Map kinase-substrate relationships with GAREM1 as a mediator

• Protein-Protein Interaction Mapping:

  • Use BioID or proximity ligation assays to identify interaction partners

  • Perform co-immunoprecipitation followed by mass spectrometry

  • Validate key interactions through reciprocal co-IP experiments

• Mathematical Modeling:

  • Develop ordinary differential equation models of GAREM1-mediated pathways

  • Incorporate experimental data to estimate rate constants

  • Use models to predict system responses under novel conditions

These approaches enable researchers to position GAREM1 within its broader signaling context, understanding not just individual interactions but how these collectively influence cellular behavior in normal physiology and disease states .

How should researchers approach contradictory findings in GAREM1 research?

Contradictory findings in GAREM1 research may arise from multiple sources and require systematic resolution approaches:

Common Sources of Contradictions:

• Methodological Differences:

  • Antibody specificity and epitope accessibility

  • Cell type-specific expression patterns

  • Experimental conditions (serum levels, cell density)

  • Detection techniques and sensitivity thresholds

• Biological Complexity:

  • Isoform-specific functions not distinguished in the study

  • Context-dependent roles in different cell types

  • Compensatory mechanisms after genetic manipulation

  • Post-translational modification status

Resolution Framework:

• Systematic Comparison:

  • Create a detailed comparison table of contradictory studies

  • Highlight key methodological differences

  • Identify potential sources of discrepancy

• Replication with Controls:

  • Reproduce each contradictory finding using standardized protocols

  • Include appropriate positive and negative controls

  • Document all experimental conditions meticulously

• Bridging Experiments:

  • Design experiments that specifically address identified differences

  • Test whether contradictions are context-dependent rather than truly contradictory

  • Develop unified models that explain apparent contradictions

Example Resolution Table:

By systematically addressing contradictions rather than dismissing them, researchers can develop more nuanced and comprehensive understanding of GAREM1's complex biological functions .

What emerging technologies might advance GAREM1 antibody-based research?

Emerging technologies offer new opportunities to enhance GAREM1 research beyond traditional antibody applications:

Advanced Imaging Technologies:

• Super-resolution Microscopy:

  • Techniques like STORM, PALM, or STED provide 10-20nm resolution

  • Applications for GAREM1:

    • Precise mapping of protein clusters at membrane microdomains

    • Nanoscale co-localization with signaling partners

    • Single-molecule tracking of GAREM1 dynamics

• Live-cell Imaging Approaches:

  • CRISPR-based endogenous tagging of GAREM1 with fluorescent proteins

  • Proximity sensors to detect real-time protein interactions

  • FRET/FLIM to measure conformational changes upon activation

Single-cell Analysis Technologies:

• Mass Cytometry (CyTOF):

  • Metal-conjugated antibodies allow simultaneous detection of 40+ proteins

  • Applications for GAREM1:

    • Correlation with multiple pathway components at single-cell level

    • Identification of cell subpopulations with distinct signaling states

    • Analysis of rare cell populations in heterogeneous samples

• Spatial Transcriptomics with Protein Detection:

  • Combined RNA and protein analysis with spatial resolution

  • Correlate GAREM1 protein expression with transcriptional states

  • Map tissue microenvironments and their influence on GAREM1 function

Proteomics Innovations:

• Targeted Proteomics:

  • Antibody-free quantification using selected reaction monitoring (SRM)

  • Development of GAREM1-specific peptide standards for absolute quantification

  • Higher reproducibility for quantitative studies across laboratories

• Crosslinking Mass Spectrometry:

  • Map protein interaction interfaces at amino acid resolution

  • Identify structural changes in GAREM1 complexes upon activation

  • Characterize entire signalosome assemblies containing GAREM1

These technologies promise to overcome current limitations in GAREM1 research, providing unprecedented insights into its molecular behavior, interaction dynamics, and functional heterogeneity across different cellular contexts .

What are the most promising research directions for understanding GAREM1's role in disease pathogenesis?

Current evidence suggests several high-potential research directions for investigating GAREM1's involvement in disease:

Cancer Research Priorities:

• Expression Profiling Across Cancer Types:

  • Comprehensive analysis of GAREM1 expression in tumor tissue microarrays

  • Correlation with clinical outcomes and treatment responses

  • Isoform-specific expression patterns in different cancer subtypes

• Functional Studies in Oncogenic Signaling:

  • GAREM1's role in mediating resistance to targeted therapies

  • Contribution to cancer cell migration and invasion

  • Potential as a therapeutic target or biomarker

Metabolic Disease Investigations:

• Insulin Signaling Pathway:

  • GAREM1's potential role in insulin receptor signaling

  • Effects on glucose metabolism in insulin-responsive tissues

  • Alterations in expression or function in diabetes models

• Metabolic Stress Responses:

  • GAREM1 regulation under conditions of nutrient limitation

  • Role in coordinating growth factor and metabolic signaling

  • Potential therapeutic target for metabolic disorders

Neurodegenerative Disease Applications:

• Neuronal Signaling Studies:

  • GAREM1 expression and function in different neuronal populations

  • Role in neurotrophin signaling and neuronal survival

  • Potential alterations in neurodegenerative disease models

• Neuroinflammation Connection:

  • GAREM1 function in glial cells and neuroinflammatory responses

  • Interaction with disease-associated signaling pathways

  • Potential as a therapeutic target for neuroinflammatory conditions

For all these research directions, GAREM1 antibodies serve as critical tools for detecting expression patterns, monitoring subcellular localization, and identifying interaction partners in relevant disease models and patient samples .